Showing 2461-2470 of 7016 results for "".
Growth Factors as a Cornerstone in Cost-Effective Regenerative Medicine
https://reachmd.com/ma-issues-index/jan-feb-2026-issue/growth-factors-as-a-cornerstone-in-cost-effective-regenerative-medicine/54432/Sex, Skin, and the Endocrine Engine
https://reachmd.com/ma-issues-index/september-october-2025/sex-skin-and-the-endocrine-engine/39266/Why aesthetics needs a hormone upgradeElevating Acute Seizure Response in Epilepsy Care
https://reachmd.com/programs/practical-neurology/elevating-acute-seizure-response-in-epilepsy-care/39943/Not the Average Investor
https://reachmd.com/topics/practice-development/not-the-average-investor/35173/Why physicians need a different approach to investingVerrucous Psoriasis: A Rare Variant Refractory to Topical Steroids
https://reachmd.com/programs/practical-dermatology-focus-psoriasis/verrucous-psoriasis-a-rare-variant-refractory-to-topical-steroids/29204/In this case study, researchers present a patient with VP of the dorsal fingers that was initially diagnosed as psoriasis and treated with multiple topical steroids. Ultimately, the patient was refractory to steroid topical therapy and required consideration of alternative treatments for definitiveIn Focus: Advances in Aesthetic Medicine
https://reachmd.com/topics/skincare/in-focus-advances-in-aesthetic-medicine/35184/Onboarding Aesthetic Physician Extenders: Developing a Plan
https://reachmd.com/topics/practice-development/onboarding-aesthetic-physician-extenders-developing-a-plan/35172/A review of the benefits of having a formal training programTwo Types of Tax-Advantaged Benefit Plans: Why Aesthetic Practices Should Consider Both
https://reachmd.com/topics/practice-development/two-types-of-tax-advantaged-benefit-plans-why-aesthetic-practices-should-consider-both/35155/A look at ways to reduce taxes an increase retirement savingsNeo-Romanticism in Aesthetic Medicine
https://reachmd.com/ma-issues-index/september-october-2025/neo-romanticism-in-aesthetic-medicine/39267/A cultural reawakening as patients want to feel human and authenticShared Decision-Making in Pulmonary Arterial Hypertension: Strategies for PAH Treatment Initiation and Support
https://reachmd.com/programs/medical-industry-feature/shared-decision-making-in-pah-treatment-initiation/36303/Early diagnosis and intervention are critical for improving outcomes for patients with pulmonary arterial hypertension (PAH).1,2 Evidence-based guidelines recommend adding UPTRAVI® (selexipag)—a prostacyclin receptor agonist—at first follow-up for appropriate patients presenting at intermediate-low